Advanced Health Intelligence Ltd AHI
At closeJul 25, 2024, 4:00 PM EDT
52-week range unavailable
- Market cap
- 345.76M
- Revenue (ttm)
- -924.86K
- Shares out
- 8.53M
- Previous close
- 1.50
- Day's range
- 1.50 – 1.50
- Beta
- 1.61
- Analysts
- Hold
- Price target
- 8.04 (+436.0%)
Key statistics
- Enterprise value
- 361.39M
- PEG ratio
- 0.00
- Price / sales
- -14.16
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -91.30%
- Free cash flow
- -1.96M
- Total cash
- 461.01K
- Total debt
- 3.66M
- Return on equity
- -1045.50%
- Short % of float
- 0.00%
- 50-day average
- 1.50
- 200-day average
- 1.50
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Advanced Health Intelligence Ltd
Advanced Health Intelligence Ltd. operates as a mobile application and technology development company in Australia and internationally. It offers biometric health assessments, a multi-step process that employs facial scanning, heart rate measurements, body composition analysis, and cardiovascular fitness tests that evaluates an individual's health. The company also provides FaceScan, process that estimates on heart rate, respiration rate, blood pressure, and other through facial scans; BodyScan, a smart body composition and dimensioning technology that enables user to check and assess body dimensions using a smartphone; and DermaScan, a dermatological scanner. It serves mobile health and telehealth, life and health insurance, wellness, and government sectors. The company was formerly known as Advanced Human Imaging Limited and changed its name to Advanced Health Intelligence Ltd. in December 2022. Advanced Health Intelligence Ltd. was incorporated in 2014 and is based in South Perth, Australia.
- Sector
- Technology
- Industry
- Software - Application
- Country
- Australia
- Website
- ahi.tech
News
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X 
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i 
DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update 
Advanced Health Intelligence CEO to Deliver Investor Presentation in Atlantic City 
Advanced Health Intelligence Signs Binding Term Sheet with Electronic Medical Record and Global Personal Health Record Company OneClinic for Vietnam 
Dr. Walid Abbas Zaher Honored as a Top Healthcare Leader by Forbes Middle East 
Advanced Health Intelligence to provide Biometric Health Screening in new Collaboration between Bearn and OnCore Innovations Inc. 
Advanced Health Intelligence Issues a Retraction 
Advanced Health Intelligence to Play a Pivotal Role in Bearn Collaboration with AIG Insurance 
Advanced Health Intelligence Ltd Selected as Finalist for Singapore Ministry of Health Project
Your note
Sign in to keep a note on AHI — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Morgan Stanley | 0.03% | 2,918 | 4.38K | Mar 30, 2024 |
| Rhumbline Advisers | 0.02% | 1,965 | 2.95K | Mar 30, 2024 |
| Qube Research & Technologies Ltd | 0.00% | 38 | 57 | Mar 30, 2024 |